BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH)
16 September 2021 - 7:30AM
Business Wire
- Biocorp and Merck will collaborate on the
development and global distribution of a specific version of Mallya
device for applications in the field of HGH
- Biocorp will receive €3 million following the
completion of different milestones and additional revenues from
sales.
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French
company specialized in the design, development, and manufacturing
of innovative medical devices, and Merck, a leading science and
technology company, today announce an agreement for the development
and supply of a specific version of Mallya device to monitor
treatment adherence in the field of HGH.
Manufactured in Clermont-Ferrand (France), Mallya is a Bluetooth
enabled clip-on device for pen injectors that collects dose and
time of each injection and transfers information in real time to a
companion software. Mallya is the first in its category to receive
the CE-mark (medical device) and commercial versions for insulin
pen injectors are already available and distributed in Europe and
other geographies.
Healthcare companies BIOCORP and Merck will develop a specific
version for applications in the field of Human Growth Hormone. The
device will help patients (children and teenagers) automatically
keep track of their HGH daily injection and monitor adherence with
their treatment plan.
Following the completion of different milestones, Merck will pay
around €3 million for the development of the specific solution.
After the development phase, BIOCORP will manufacture the
commercial units on behalf of Merck, which will generate additional
revenues.
Once the development Is completed, the objective Is to market
the product on a Global scale
“We are very excited about this new agreement concerning Mallya.
Not only are we collaborating with a new major player in the
pharmaceutical industry, but we are also expanding the scope of
Mallya. After the monitoring of patients living with diabetes, our
medical device proves its usefulness and safety for children and
teenagers undergoing growth hormone injection,” said Éric
Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP Recognized for its expertise in the development
and manufacture of medical devices and delivery systems, BIOCORP
has today acquired a leading position in the connected medical
device market thanks to Mallya. This smart sensor for insulin
injection pens allows reliable monitoring of injected doses and
thus offers better compliance in the treatment of patients with
diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's
product portfolio of innovative connected solutions. The company
has 70 employees. BIOCORP is listed on Euronext since July 2015
(FR0012788065 – ALCOR). For more information, please visit
www.biocorpsys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210915006165/en/
CONTACTS BIOCORP Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne Chief Executive Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 46 26
Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66
59 22
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024